Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co.,Ltd. (4527.T) Financial Performance & Income Statement Overview
Review Rohto Pharmaceutical Co.,Ltd. (4527.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Rohto Pharmaceutical Co.,Ltd. (4527.T) Income Statement & Financial Overview
View the income breakdown for Rohto Pharmaceutical Co.,Ltd. 4527.T across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $82.73B | $86.81B | $70.73B | $68.36B |
| Cost of Revenue | $37.47B | $36.32B | $31.29B | $29.28B |
| Gross Profit | $45.26B | $50.49B | $39.43B | $39.08B |
| Gross Profit Ratio | $0.55 | $0.58 | $0.56 | $0.57 |
| R&D Expenses | $3.24B | $3.53B | $4.52B | $0.00 |
| SG&A Expenses | $35.48B | $31.95B | $28.89B | $27.45B |
| Operating Expenses | $38.72B | $36.01B | $33.43B | $27.29B |
| Total Costs & Expenses | $76.19B | $72.34B | $64.72B | $56.57B |
| Interest Income | $241.00M | $274.00M | $269.00M | $439.00M |
| Interest Expense | $385.00M | $0.00 | $63.00M | $65.00M |
| Depreciation & Amortization | $4.64B | $2.17B | $2.22B | $2.25B |
| EBITDA | $12.56B | $16.52B | $8.16B | $13.80B |
| EBITDA Ratio | $0.15 | $0.19 | $0.12 | $0.20 |
| Operating Income | $6.54B | $14.48B | $6.001B | $11.63B |
| Operating Income Ratio | $0.08 | $0.17 | $0.08 | $0.17 |
| Other Income/Expenses (Net) | $995.00M | $1.74B | $483.00M | $302.00M |
| Income Before Tax | $7.54B | $16.22B | $6.48B | $12.09B |
| Income Before Tax Ratio | $0.09 | $0.19 | $0.09 | $0.18 |
| Income Tax Expense | $1.20B | $4.42B | $2.16B | $3.61B |
| Net Income | $6.20B | $11.88B | $4.44B | $8.48B |
| Net Income Ratio | $0.07 | $0.14 | $0.06 | $0.12 |
| EPS | $27.34 | $51.95 | $19.39 | $37.18 |
| Diluted EPS | $27.04 | $51.95 | $19.40 | $37.08 |
| Weighted Avg Shares Outstanding | $229.21M | $228.76M | $228.14M | $228.14M |
| Weighted Avg Shares Outstanding (Diluted) | $229.21M | $228.76M | $228.85M | $228.75M |
Financial performance has remained strong, with revenue growing from $68.36B in Q1 2024 to $82.73B in Q4 2024. Gross profit continued to perform well, with margins at 55% in the latest quarter. Operating income reached $6.54B in Q4 2024, holding a steady 8% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $12.56B. Net income dropped to $6.20B, keeping EPS at $27.34. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan